AQST logo

Aquestive Therapeutics, Inc.

AQST
Healthcare|Drug Manufacturers - Specialty & Generic|US
$3.61
-0.05 (-1.37%)
Cash / Share
$0.72
Next Earnings Report
Mar 3, 2027
EPS est. -$0.11 · Revenue est. $13.7M
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Jul 9, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting
Nov 5, 2026 · GlobeNewsWire
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 3, 2026 · GlobeNewsWire
Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
Oct 27, 2026 · GlobeNewsWire
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
Oct 15, 2026 · GlobeNewsWire
Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop
Oct 7, 2026 · PRNewsWire
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Sep 29, 2026 · GlobeNewsWire
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Sep 17, 2026 · GlobeNewsWire
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
Sep 1, 2026 · GlobeNewsWire
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 11, 2026 · GlobeNewsWire
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
Aug 10, 2026 · GlobeNewsWire

SEC Filings (68)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 20268-KMaterial eventDocumentIndex
Nov 3, 202610-QQuarterly reportDocumentIndex
Nov 3, 20268-KMaterial eventDocumentIndex
Oct 19, 20268-KMaterial eventDocumentIndex
Oct 15, 20268-KMaterial eventDocumentIndex
Oct 14, 20268-KMaterial eventDocumentIndex
Oct 7, 2026SC 13GPassive 5%+ stakeDocumentIndex
Oct 7, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Sep 29, 20268-KMaterial eventDocumentIndex
Sep 25, 20268-KMaterial eventDocumentIndex
Sep 17, 20268-KMaterial eventDocumentIndex
Aug 11, 202610-QQuarterly reportDocumentIndex
Aug 11, 20268-KMaterial eventDocumentIndex
Aug 10, 20268-KMaterial eventDocumentIndex
Jul 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 9, 2026424B3Offering prospectusDocumentIndex
Jul 8, 2026EFFECTDocumentIndex
Jun 26, 2026S-3Shelf registrationDocumentIndex
Jun 10, 20268-KMaterial eventDocumentIndex
May 13, 202610-QQuarterly reportDocumentIndex
May 13, 20268-KMaterial eventDocumentIndex
Apr 24, 2026ARSAnnual report to holdersDocumentIndex
Apr 24, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 24, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 30, 20268-KMaterial eventDocumentIndex
Mar 20, 20268-KMaterial eventDocumentIndex
Mar 4, 2026S-8Employee stock planDocumentIndex
Mar 4, 202610-KAnnual reportDocumentIndex
Mar 4, 20268-KMaterial eventDocumentIndex
Feb 26, 20268-KMaterial eventDocumentIndex
Feb 2, 20268-KMaterial eventDocumentIndex
Jan 21, 2026S-8Employee stock planDocumentIndex
Jan 9, 20268-KMaterial eventDocumentIndex
Nov 14, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 6, 20258-KMaterial eventDocumentIndex
Nov 5, 202510-QQuarterly reportDocumentIndex
Nov 5, 20258-KMaterial eventDocumentIndex
Oct 17, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Oct 8, 20258-KMaterial eventDocumentIndex
Oct 1, 20258-KMaterial eventDocumentIndex